OTCMKTS:CPMV Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free CPMV Stock Alerts $0.40 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$0.31▼$0.6052-Week Range$0.10▼$1.00Volume1,553 shsAverage Volume1,184 shsMarket Capitalization$2.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsStock AnalysisChartEarningsFinancialsSEC Filings Get Mosaic ImmunoEngineering alerts: Email Address Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About Mosaic ImmunoEngineering Stock (OTCMKTS:CPMV)Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Read More CPMV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPMV Stock News HeadlinesMay 14 at 5:43 PM | msn.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 13 at 7:07 PM | msn.comNanoparticle plant virus treatment shows promise in fighting metastatic cancers in miceApril 29, 2024 | finanznachrichten.deMosaic ImmunoEngineering Inc.: Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.April 29, 2024 | finance.yahoo.comOncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.December 20, 2023 | bbc.comOlney: Roman villa mosaic found under Aldi supermarket siteNovember 12, 2023 | morningstar.comMosaic ImmunoEngineering Inc Ordinary Shares CPMVOctober 31, 2023 | morningstar.comThe Mosaic Co MOSAugust 23, 2023 | mirror.co.ukLacey Turner shows off quirky North London home with £5 furniture and mosaic printsApril 11, 2023 | finance.yahoo.comMosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101March 22, 2023 | seekingalpha.comCPMV Mosaic ImmunoEngineering Inc.March 17, 2023 | benzinga.comMosaic Unusual Options Activity For March 15March 5, 2023 | finance.yahoo.comMosaic ImmunoEngineering Inc. (CPMV)January 2, 2023 | foxnews.comNOAA satellite captures Earth mosaic showing stunning panoramic viewOctober 31, 2022 | finance.yahoo.comMosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology PlatformOctober 31, 2022 | finance.yahoo.comUPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology PlatformOctober 17, 2022 | abcnews.go.comSyria digs up 'rare' Roman mosaic in former rebel strongholdOctober 6, 2022 | finance.yahoo.comMosaic sees lower phosphate output, late shipments after Hurricane Ian hitSeptember 26, 2022 | benzinga.comMosaic ImmunoEngineering Stock (OTC:CPMV), Guidance and ForecastSeptember 22, 2022 | dailymail.co.ukOrnate Byzantine floor mosaic dating from the 5th to 7th century AD is discovered by a Palestinian farmer in an olive grove in the Gaza StripJuly 8, 2022 | investing.comMosaic Immunoengineering Inc (CPMV)May 5, 2022 | finance.yahoo.comMosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve UniversityMarch 31, 2022 | finance.yahoo.comNewly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in MelanomaSee More Headlines Receive CPMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mosaic ImmunoEngineering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CPMV CUSIPN/A CIK836564 Webwww.ptsc.com Phone(657) 208-0890Fax760-547-2705Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,010,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-410.17% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-0.49Miscellaneous Outstanding Shares7,240,000Free Float1,377,000Market Cap$2.90 million OptionableNot Optionable Beta0.06 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Steven W. King (Age 60)Chairman of the Board, President & CEO Comp: $267.84kMr. Paul J. Lytle CPA (Age 56)Executive VP, CFO, Secretary & Director Comp: $295.53kJay CarlsonSenior Manager of Investor RelationsMr. Joseph S. Shan M.P.H. (Age 51)Head of Clinical Operations Dr. Marvin R. Garovoy M.D. (Age 80)Head of Medical Immuno-Oncology Cyril Empig Ph.D.Head of Vaccine DevelopmentMore ExecutivesKey CompetitorsEloxx PharmaceuticalsNASDAQ:ELOXAvalon GloboCareNASDAQ:ALBTFinch Therapeutics GroupNASDAQ:FNCHKiromic BioPharmaNASDAQ:KRBPGamida CellNASDAQ:GMDAQView All Competitors CPMV Stock Analysis - Frequently Asked Questions How have CPMV shares performed in 2024? Mosaic ImmunoEngineering's stock was trading at $0.60 at the beginning of 2024. Since then, CPMV shares have decreased by 33.3% and is now trading at $0.40. View the best growth stocks for 2024 here. How were Mosaic ImmunoEngineering's earnings last quarter? Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) issued its earnings results on Monday, April, 15th. The company reported ($0.04) EPS for the quarter. How do I buy shares of Mosaic ImmunoEngineering? Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CPMV) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mosaic ImmunoEngineering, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
